SF 1019

Drug Profile

SF 1019

Alternative Names: R-1818; SF-1019

Latest Information Update: 10 Apr 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Argyll Biotechnologies LLC
  • Developer Argyll Biotechnologies
  • Class Anti-inflammatories; Lipoproteins; Non-opioid analgesics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies; Inflammation; Skin ulcer

Most Recent Events

  • 13 Aug 2008 Registered for Diabetic neuropathies in Malaysia (SC)
  • 13 Aug 2008 Registered for Inflammation in Malaysia (SC)
  • 13 Aug 2008 Registered for Skin ulcer in Malaysia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top